MAGNETIC RESONANCE SPECTROSCOPY IN HUMAN LYMPHOMAS

人类淋巴瘤的磁共振波谱检查

• 批准号: 2099309
• 负责人: WILLIAM G NEGENDANK
• 金额: $ 32.32万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-07-15 至 1996-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2099309
• 关键词: clinical biomedical equipment; disease /disorder classification; human subject; magnetic resonance imaging; neoplasm /cancer radiodiagnosis; nonHodgkin's lymphoma; nuclear magnetic resonance spectroscopy; nuclear medicine; phosphorus metabolism; prognosis; technology /technique; technology /technique development

Non-Hodgkin's Lymphoma (NHL) provides an excellent model with which to probe variations in cancer metabolism in vivo using NMR and to examine potential clinical and research uses of 31P magnetic resonance spectroscopy (MRS). NHL occurs in 3 grades with distinctly different histologic, biologic and clinical features. It is now well established that 31P NMR spectra of human cancers in vivo typically have metabolic characteristics which differ from those of normal tissues including elevated phosphomonoesters (PME), elevated phosphodiesters (PDE) and diminished phosphocreatine (PCR). In several studies, including those of lymphomas, one or more of these characteristics have been shown to provide useful diagnostic discriminants or prognostic indices. This background makes it clear that it is time to address the question "What is the clinical utility of NMR spectroscopy in oncology?". The study we propose is a prospective trial in a large number of patients with a type of cancer (NHL) especially well suited to address this question, with careful attention paid to patient selection, protocol management and statistical analysis. To achieve the aims of this study, we will first develop dual-tuned 1H, 31P surface coils appropriate to access the wide variety of anatomic locations of NHL's, along with proton decoupling of 31P to distinguish individual components of the phospholipid metabolites (e.g., phosphocholine and phosphoethanolamine), 3D chemical shift imaging to localize 31P NMR spectra to the lymphoma mass, and quantitation of metabolites. We will test the hypothesis that malignant behavior correlates with metabolic status in the clinical setting by determining how the 3 grades of NHL differ in their 31P NMR spectra in regard to phospholipid metabolites, energy metabolites, and pH. We will test the hypothesis that the 31P NMR spectrum of NHL contains prognostic information that can predict response to treatment or eventual clinical outcome by relating these events to metabolic features in the baseline spectrum and to changes that occur in the spectrum upon initiation of treatment. Results of this study will pave the way for large clinical trials of MRS in other cancers, and for a clinical trial in which 31P MRS could be used to intervene in the selection of treatment regimens in individual patients with NHL.

非霍奇金淋巴瘤（NHL）提供了一个极好的模型 使用NMR在体内的癌症代谢方面的探针变化并检查 31p磁共振的潜在临床和研究用途 光谱法（MRS）。 NHL发生在3年级，截然不同 组织学，生物学和临床特征。 现在已经建立了 体内人类癌的31p NMR光谱通常具有代谢 与正常组织不同的特征 磷酸盐升高（PME），磷酸化升高（PDE）和 磷酸磷酸盐（PCR）减少。 在几项研究中，包括 在淋巴瘤中，这些特征中的一个或多个已显示为 提供有用的诊断判别因子或预后指数。 这 背景清楚地表明，是时候解决这个问题了。 NMR光谱在肿瘤学中的临床实用性是否？”。 建议是大量类型患者的前瞻性试验 癌症（NHL）特别适合解决这个问题， 仔细注意患者选择，方案管理和 统计分析。 为了实现这项研究的目的，我们将首先 开发双音调的1H，31p表面线圈，适合访问宽度 NHL的各种解剖位置，以及质子脱钩 31p区分磷脂代谢产物的各个成分 （例如，磷胆碱和磷酸乙醇胺），3D化学移位成像 将31p NMR光谱定位到淋巴瘤质量，并定量 代谢物。 我们将测试恶性行为的假设 通过确定在临床环境中与代谢状态相关 NHL的3年级在其31p NMR光谱方面有何不同 磷脂代谢物，能量代谢产物和pH。 我们将测试 假设NHL的31p NMR光谱包含预后 可以预测对治疗或最终临床反应的信息 通过将这些事件与基线中的代谢特征联系起来的结果 频谱和对频谱中发生的变化 治疗。 这项研究的结果将为大型临床铺平道路 其他癌症中MRS的试验，以及31p MRS的临床试验 可用于干预治疗方案的选择 患有NHL的个别患者。